Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Equity Ratio (2022 - 2025)

Taysha Gene Therapies' Equity Ratio history spans 4 years, with the latest figure at 0.69 for Q3 2025.

  • For Q3 2025, Equity Ratio rose 40.4% year-over-year to 0.69; the TTM value through Sep 2025 reached 0.69, up 40.4%, while the annual FY2024 figure was 0.45, 2.81% up from the prior year.
  • Equity Ratio for Q3 2025 was 0.69 at Taysha Gene Therapies, down from 0.75 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.75 in Q2 2025 and bottomed at 0.46 in Q2 2023.
  • The 4-year median for Equity Ratio is 0.35 (2024), against an average of 0.26.
  • The largest YoY upside for Equity Ratio was 5672.72% in 2023 against a maximum downside of 361.28% in 2023.
  • A 4-year view of Equity Ratio shows it stood at 0.01 in 2022, then surged by 5672.72% to 0.43 in 2023, then grew by 2.81% to 0.45 in 2024, then soared by 55.1% to 0.69 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Equity Ratio are 0.69 (Q3 2025), 0.75 (Q2 2025), and 0.4 (Q1 2025).